Issuer:
|
Tekmira Pharmaceuticals Corporation ("Tekmira" or the “Company”).
|
Offering:
|
Units of the Company (the “Units”). Each Unit will consist of one common share in the capital of the Company (a “Common Share”) and a portion of a Common Share purchase warrant.
|
Offering Price:
|
To be determined in the context of the market.
|
Amount:
|
Approximately CAD$5,000,000.
|
Type of Offering:
|
Public offering made in accordance with National Instrument 44-101 Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions and the Multijurisdictional Disclosure System adopted by the United States and Canada.
|
Use of Proceeds:
|
The Company intends to use the net proceeds of the Offering for general corporate purposes, ongoing research and development programs, and working capital requirements.
|
Listing:
|
The Common Shares of the Company currently trade on the TSX under the symbol "TKM" and the Nasdaq Capital Market under the symbol “TKMR”. Closing is conditional upon the Common Shares forming part of the Units and the Common Shares issuable upon exercise of the Warrants forming part of the Units being approved for listing on the TSX and Nasdaq subject only to the customary listing conditions.
|
Eligibility:
|
Eligible under the usual statutes and for TFSAs, RRSPs, RRIFs, RESPs and DPSPs.
|
Jurisdictions:
|
The Offering will be made in all of the provinces of Canada, except Quebec, the United States, and those jurisdictions outside of Canada and outside of the United States as may be agreed to by the Company and Versant.
|
Agent:
|
The Company has engaged Versant Partners Inc. to act as its placement agent in connection with the Offering in Canada and jurisdictions outside of Canada and the United States. There is no placement agent for the Offering in the United States.
|
Closing Date:
|
On or about Wednesday, June 15, 2011.
|